Comparison of demographics, disease characteristics and treatments of PsC patients by likelihood of anxiety.
| Variables | Frequency (%) or Mean (SD) | p | ||
|---|---|---|---|---|
| Unlikely Anxiety (HADS ≤ 7), n = 102 | Possible Clinical Anxiety (HADS 8–10), n = 21 | Probable Clinical Anxiety (HADS ≥ 11), n = 12 | ||
| Age, yrs | 54.3 (12.9) | 54.1 (12.9) | 51.5 (13.1) | 0.85 |
| Age at diagnosis of PsC, yrs | 28.0 (14.0) | 27.9 (13.0) | 24.6 (13.9) | 0.16 |
| Sex (female) | 43 (42.6%) | 15 (76.2%) | 10 (83.3%) | 0.0013 |
| Unemployed | 28 (27.7%) | 5 (23.8%) | 6 (50%) | 0.23 |
| Education status (college/university) | 90 (88.2%) | 19 (90.5%) | 8 (66.7%) | 0.10 |
| Married/common-law | 55 (54.5%) | 14 (66.7%) | 8 (66.7%) | 0.47 |
| Smoking status | 0.29 | |||
| Nonsmoker | 52 (51.5%) | 9 (42.9%) | 4 (33.3%) | |
| Current | 15 (14.9%) | 1 (4.8%) | 3 (25%) | |
| Past | 34 (33.7%) | 11 (52.4%) | 5 (41.7%) | |
| Alcohol consumption | 0.051 | |||
| None | 35 (34.3%) | 6 (28.6%) | 9 (75%) | |
| Social | 55 (53.9%) | 1 (4.8%) | 3 (25%) | |
| Daily | 10 (9.8%) | 4 (19.1%) | 0 (0%) | |
| PASI | 3.3 (4.0) | 3.1 (3.5) | 3.8 (5.3) | 0.58 |
| Physician global assessment (fair-very poor) | 2 (2%) | 0 (0%) | 0 (0%) | NS |
| HAQ | 0.44 (0.56) | 0.81 (0.69) | 1.04 (0.68) | 0.0002 |
| HAQ pain (0–100) | 25.5 (24.3) | 28.0 (24.3) | 51.1 (28.9) | < 0.0001 |
| SF-36 MCS | 53.4 (7.8) | 43.0 (10.8) | 38.0 (11.2) | < 0.0001 |
| SF-36 PCS | 43.3 (11.8) | 38.7 (12.6) | 34.7 (10.6) | 0.12 |
| Patient’s global assessment (fair-very poor) | 11 (10.8%) | 4 (19.1%) | 6 (54.5%) | 0.003 |
| DLQI | 2.6 (3.8) | 4.2 (5.3) | 6.1 (6.8) | < 0.0001 |
| FSS | 3.5 (2.9) | 5.66 (12.7) | 22.2 (12.9) | < 0.0001 |
| Ultraviolet therapy | 24 (23.8%) | 3 (14.3%) | 3 (25%) | 0.68 |
| Topicals for psoriasis | 85 (84.2%) | 18 (85.7%) | 10 (83.3%) | NS |
| NSAID | 3 (2.9%) | 2 (10%) | 4 (33.3%) | 0.002 |
| DMARD | 13 (12.7%) | 2 (9.5%) | 4 (33.3%) | 0.18 |
| Biologic agents | 8 (7.8%) | 3 (14.3%) | 1 (8.3%) | 0.67 |
| Anti-depressants | 9 (8.9%) | 3 (14.3%) | 2 (16.7%) | 0.43 |
HADS: Hospital Anxiety and Depression Scale; PsC: psoriasis without psoriatic arthritis; PASI: Psoriasis Area and Severity Index; HAQ: Health Assessment Questionnaire; SF-36: Medical Outcomes Study Short Form-36; MCS: SF-36 mental subscale; PCS: SF-36 bodily pain subscale; DLQI: Dermatology Quality of Life Index; FSS: Fatigue Severity Scale; NSAID: nonsteroidal antiinflammatory drugs; DMARD: disease-modifying antirheumatic drugs; NS: not significant.